Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 overexpression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.

Autor: Chumakov, Ilya1 ichumakov@pharnext.com, Milet, Aude1 amilet@pharnext.com, Cholet, Nathalie1 ncholet@pharnext.com, Primas, Gwenaël1 gprimas@pharnext.com, Boucard, Aurélie1 aboucard@pharnext.com, Pereira, Yannick1 ypereira@pharnext.com, Graudens, Esther1 egraudens@pharnext.com, Mandel, Jonas1 jmandel@pharnext.com, Laffaire, Julien1 jlaffaire@pharnext.com, Foucquier, Julie1 jfoucquier@pharnext.com, Glibert, Fabrice1 fglibert@pharnext.com, Bertrand, Viviane1 vbertrand@pharnext.com, Nave, Klaus-Armin2 nave@em.mpg.de, Sereda, Michael W.2,3 sereda@em.mpg.de, Vial, Emmanuel1 evg.vial@gmail.com, Guedj, Mickaël1 mguedj@pharnext.com, Hajj, Rodolphe1 rhajj@pharnext.com, Nabirotchkin, Serguei1 snabirotchkin@pharnext.com, Cohen, Daniel1 dcohen@pharnext.com
Zdroj: Orphanet Journal of Rare Diseases. 2014, Vol. 9 Issue 1, p282-311. 30p.
Databáze: Academic Search Ultimate